GPR

NXE0041178 is a potent full agonist of the GPR52 receptor, exhibiting a pEC50 of 7.5 for human GPR52 and an EC50 of 27.5 nM for rat GPR52. This compound demonstrates an ability to penetrate the blood-brain barrier and shows minimal inhibition of hERG, hNaV1.5, and cytochrome P450 isoforms. Notably, NXE0041178 effectively reduces d-amphetamine-induced hyperactivity in rat models, making it a valuable tool for research related to neurological disorders.

GPR52 Agonist-1 is a potent GPR52 agonist with an pEC50 value of 7.53, demonstrating oral bioactivity and the ability to penetrate the blood-brain barrier. This compound enhances cAMP accumulation through direct engagement with the GPR52 receptor. GPR52 Agonist-1 has shown significant efficacy in suppressing methamphetamine-induced hyperactivity in murine models, indicating potential antipsychotic effects. It serves as a valuable tool for research into psychotropic medications and related neurological conditions.